tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
US Market
MLYS
Mineralys Therapeutics, Inc.
Overview
Analyst Forecasts
AI Stock Analysis
News & Insights
Financials
Dividends
Technical Analysis
Options
Chart
Earnings
Ownership
Stock Buybacks
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

Mineralys Therapeutics, Inc. (MLYS) Stock News & Sentiment

Compare
311 Followers
Buy Rating Affirmed for Mineralys Therapeutics, Inc. Due to Promising Lorundrostat Study Outcomes
Premium
Ratings
Buy Rating Affirmed for Mineralys Therapeutics, Inc. Due to Promising Lorundrostat Study Outcomes
3d ago
MLYS
Promising Potential of Lorundrostat Drives Buy Rating for Mineralys Therapeutics, Inc.
Premium
Ratings
Promising Potential of Lorundrostat Drives Buy Rating for Mineralys Therapeutics, Inc.
3d ago
MLYS
Mineralys Therapeutics Reports Positive Phase 3 Trial Results
Premium
Company Announcements
Mineralys Therapeutics Reports Positive Phase 3 Trial Results
4d ago
8K
MLYS
Buy Rating for Mineralys Therapeutics, Inc. Driven by Lorundrostat’s Potential in Hypertension Treatment
Premium
Ratings
Buy Rating for Mineralys Therapeutics, Inc. Driven by Lorundrostat’s Potential in Hypertension Treatment
8d ago
MLYS
3 Best Stocks to Buy Now, 2/26/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 2/26/2025, According to Top Analysts
16d ago
BABA
BLZE
Mineralys Therapeutics Highlights Positive Earnings Call
Premium
Company Announcements
Mineralys Therapeutics Highlights Positive Earnings Call
28d ago
MLYS
Promising Outlook for Mineralys Therapeutics: Buy Rating Affirmed on Lorundrostat’s Potential
Premium
Ratings
Promising Outlook for Mineralys Therapeutics: Buy Rating Affirmed on Lorundrostat’s Potential
29d ago
MLYS
More MLYS News >

MLYS News on the Web

Mineralys Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock
Quiver Quantitative
Neutral
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
Yahoo Finance
Neutral
Sector Update: Health Care Stocks Decline Late Afternoon
Yahoo Finance
Neutral
Mineralys’s stock soars as hypertension pill scores in two pivotal trials
Clinical Trials Arena
Neutral
Goldman Sachs Remains a Buy on Mineralys Therapeutics, Inc. (MLYS)
TipRanks News
Neutral
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
Yahoo Finance
Neutral
Mineralys shares climb on study data for blood pressure drug
BioPharma Dive
Neutral
Mineralys Therapeutics Highlights Positive Earnings Call
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
MLYS
Sector Average
Media Buzz
This Week7 articles
Weekly Average1.75 articles
News Sentiment
This Week50%
Sector Average54%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MLYS’s Media Buzz Sentiment?
7 articles about MLYS were published this week. In an average week, 1.75 articles are published.
    What is MLYS’s weekly average amount of articles?
    In an average week, 1.75 articles about MLYS are published.
      What is MLYS’s News Sentiment?
      50% of articles about MLYS were positive this week, compared to its sector average of 54%.
        Healthcare Stocks that are Trending in the News
        PTGXProtagonist Therapeutics
        OPRXOptimizeRx
        CKPTCheckpoint Therapeutics
        CSBTFKuros Biosciences
        FENCFennec Pharmaceuticals
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing